Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies

by on 29 de setembre de 2025 with No hi ha comentaris
  • Luke, J., Gelmon, K., Siu, L., Moreno, V., Desai, J., Gomez-Roca, C.,…Tabernero, J. (2025). Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies. Clinical Cancer Research, 31(11), 2134-2144. https://doi.org/10.1158/1078-0432.CCR-24-0439

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *